Generic substitution of prescription drugs
|
|
- Alicia Waters
- 8 years ago
- Views:
Transcription
1 Generic substitution of prescription drugs Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (2)2003 Author(s): Ilmo Keskimäki and Lauri Vuorenkoski Health Policy Issues: Pharmaceutical Policy, Remuneration / Payment Current Process Stages Idea Pilot Policy Paper Legislation Implementation Evaluation Change Featured in half-yearly report: Health Policy Developments Issue 2 1. Abstract To contain the increasing costs, improve cost-effectiveness of prescription drug use, and encourage price competition among pharmaceutical producers, the Finnish government introduced a generic substitution system obliging pharmacies to substitute a prescribed drug with the cheapest/close to the cheapest corresponding one at the list of substitutable pharmaceuticals. 2. Purpose of health policy or idea The main objectives of the introduction of generic substitution are to improve cost-effective use of medicines and to encourage price competition in order to contain the rapidly increasing costs of prescription drugs and its burden to the national health insurance. The pharmacies are obliged to substitute a prescribed drug with the cheapest or close to the cheapest corresponding medicine of the same pharmaceutical substance included in the list of substitutable medicines issued by the National Agency for Medicines. The price limits for generic substitution for each pharmaceutical substance are defined in every three months by the Social Insurance Institution (SII) managing the national health insurance. The SII calculates the maximum price by adding 2 euros to the price of the cheapest product at that moment (and 3 euros if the price is more than 40 euros). The pharmacies offer to substitute a prescribed medicine which costs more than the defined maximum with a product costing less than the maximum. The prescribing doctor may decline generic substitution for medical or therapeutical reasons. The patient does not need any reason in order to decline substitution and he/she is refunded by the national health insurance according to the actual costs of the prescription. Before the introduction, the theoretical maximum savings due to generic substitution were expected to be about 2.5% of the total costs of medicines in Finland. Due to high co-payments for prescription drugs, generic substitution lowers also the patients' medicine costs. The main focus is in pharmaceutical companies which encourage to increase price competition. The reform hits the companies selling established brand names which do not have patent protection anymore but which are overpriced due to their strong market position
2 Main objectives 1. cost containment of increasing prescription costs; 2. legal obligation to generic substitution of listed prescription drugs. Type of incentives 1. legal obligation for pharmacies to follow generic substitution; 2. savings for patients in their drug expenditure; 3. encouraged price competition for pharmaceutical companies. Groups affected pharmaceutical companies, patients, pharmacies 3. Characteristics of this policy Degree of Innovation traditional innovative Degree of Controversy consensual highly controversial Structural or Systemic Impact marginal fundamental Public Visibility very low very high Transferability strongly system-dependent system-neutral The introduction of generic substitution may be an exception in the Finnish pharmaceutical policy tradition. The reform was followed through although it was strongly opposed by pharmaceutical industry and criticised by medical profession and pharmacists. After the adoption of the reform, and reports on drug price reductions and generated savings, the media has covered the reform more actively than during the preparation and parliamentary proceedings of the reform. The coverage has been mainly on price cuts and savings but the situation of pharmaceutical companies has also been reviewed. 4. Political and economic background Like other countries the expenditure for medicines is the fastest growing item in the health expenditure in Finland. The annual increase has been 10-12% during the last decade. According to earlier legislation there was an option for generic prescription but doctors have used it marginally. Before the introduction of generic substitution, cheap generic drugs made only 3% of the retail sells of pharmaceuticals in Finland. However, locally produced, heavily marketed and rather expensive branded - 2 -
3 generics have historically had substantial share of the market. Generic prescription has been considered as one measure to contain costs of medicines and to improve costeffectiveness of drug utilisation in several occasions by the policy documents and working groups of the Ministry of Social Affairs and Health. 5. Purpose and process analysis Idea Pilot Policy Paper Legislation Implementation Evaluation Change Origins of health policy idea Generic prescription and substitution are used in several countries. A closest example for Finland is Sweden where generic substitution was introduced in October The idea was adopted by the Ministry of Social Affairs and Health who has been the main proponent of the reform. Approach of idea The approach of the idea is described as: renewed: In Finland, the generic prescription has been possible earlier but the obligatory generic substitution by the pharmacies was an innovation. A similar reform was introduced in Sweden in Stakeholder positions The legislation on obligatory generic substitution was strongly opposed by pharmaceutical industry which was supported by the Finnish Medical Association and some prominent representatives of the profession. The organisation of the pharmacies opposed the legislation because of a higher expected work load and longer service times / customer. Some patient organisation also criticised the reform. During the legislative process, the pharmaceutical industry was lobbying very prominently which somewhat irritated the legislators and the Ministers. After the Bill was passed at the Parliament the industry continued their campaign and lobbied doctors and patients. Influences in policy making and legislation The amendments for the laws on medicines and health insurance were passed in the Parliament in late No significant changes were made to the original draft bill. Legislative outcome success Adoption and implementation The pharmacies have a legal obligation to offer generic substitution for patients. The implementation of the legislation has been dependent on patients (whether they accept substitution) and on doctors (whether they actively oppose generic substitution by denying it in prescriptions)
4 According to the statistics based on reimbursement data and published by the Social Insurance Institution, generic substitution has adopted well. During the first six months (April-September 2003) of generic substitution the patients forbade substitution in 10.6% of potential substitutable prescriptions. This proportion has gradually decreased after the introduction of the reform. Surprisingly, the physicians forbade the substitution in only 0.4% of the cases and in over 70% of potentially substitutable prescriptions the physicians already prescribed a cheap enough generic alternative not calling for substitution. The introduction of generic substitution has also had an unexpectedly strong influence on competition between pharmaceutical companies. In the first four months of generic substitution the companies decreased the prices of about 40% of 1900 substitutable products. The price decreases have also been higher than expected. For instance, the average cost per prescription of alternative products of three ACE inhibitors (drugs to treat high blood pressure) included in generic substitution decreased by 26-49% in the first three months of the reform. The corresponding decrease for the only substitutable statin used to treat high cholesterol was 30%. The prescription costs of non-substitutable pharmaceuticals in the same therapeutical groups did not change or they slightly increased. Monitoring and evaluation The use of generic substitution, sells of generic drugs and other experiences on the system are followed as normal activity of relevant government agencies. For instance, the Social Insurance Institution running the national health insurance has published monthly statistics on generic substitution. However, no specific formal review mechanism of the reform exists. Due to the smooth adoption of generic substitution by the patients, doctors and pharmacies and particularly due to increased price competition, the savings generated by the introduction of generic substitution have been higher than expected. The anticipated savings due to substitution in the preparation of the reform were 45 million euros corresponding to 2.5% of the total prescription costs. In only the first six months, the actual savings generated have been 39.4 million euros of which about two thirds were generated by drug price reductions and one third by actual substitutions to cheaper products. It is estimated that the first year savings will be nearly twice the expected. 44% of the total savings have lowered the patient's share of prescription costs and the rest, 56%, have reduced reimbursement payments by the national health insurance. The pharmaceutical industry is expecting that the growth rate of pharmaceutical sales will decrease due to generic substitution. For 2003, the industry anticipates an increase of 5% in their total sales, which is about half of the growth rate in The companies selling high priced products with generic alternatives have been losers. In several companies, the reform has even resulted decrease in sales. One of the losers is the only substantial Finnish company which has much based its market profile on highly priced generic products with established brand names. The company has given a notice for about 300 of its employees in As a whole, the principles of the Swedish and Finnish generic substitution systems are much alike and the experiences from the introduction of substitution are also similar. In Sweden, a slightly higher proportion of doctors (3%) but a smaller proportion of patients (8%) declined the substitution in the first six months of generic substitution than in Finland. While the price reductions of substitutable products have seemingly been slightly lower in Sweden than in Finland, the first year savings generated by substitution are estimated to be relatively larger in Finland corresponding 5% of the total prescription costs compared to 2% in Sweden. 6. Expected outcome According to first experiences it is obvious that generic substitution have been so far adopted more smoothly and the attitudes of medical profession have, as a whole, been less hostile than expected
5 The expected savings have also been larger than expected: the first year estimate is about 5% of total prescription costs. This is mainly due to intensive price competition between pharmaceutical companies but in addition the physicians and patients have accepted the reform better than expected. On the long run, the outcomes of generic substitution are difficult to predict. Some experts have claimed that the reform may only have a short-term effect on pharmaceutical expenditure. After a short slowing down of the growth of the expenditure due to price reductions, the growth rate assumes the earlier trend because fundamental factors behind the fast increasing expenditure have not changed. The markets may divide somewhat differently from the pre-reform situation; companies selling low price generic products sell more. However, the expenditure growth, which has mainly been based on the introduction of new expensive patent protected pharmaceuticals, may still continue. It is also expected that the role of patent protected medicines will increase as pharmaceutical industry will focus on patented drugs in its marketing. Quality of Health Care Services marginal fundamental Level of Equity system less equitable system more equitable Cost Efficiency very low very high It may be confusing that the ratings for the questions 6, 7 and 8 are not on the same scale. There is no negative end in the scale for the questions 6 and 8. I think there should be. Generic substitution is neutral in terms of equity and it is difficult to see that it could have any clear impact on quality of care but it lowers the cost of drug treatments for a number of diseases, thus it should have at least some effect on cost-efficiency. 7. References Sources of Information Most material is in Finnish. A short description and statistical information on the outcomes of the generic substitution system can be found at the web page of the Research Department of the Social Insurance Institution of Finland ( Reform formerly reported in Generic Substitution of Prescription Drugs Author/s and/or contributors to this survey Ilmo Keskimäki and Lauri Vuorenkoski Suggested citation for this online article Ilmo Keskimäki and Lauri Vuorenkoski. "Generic substitution of prescription drugs". Health Policy Monitor, Oktober Available at -
Electronic prescriptions and patient records
Electronic prescriptions and patient records Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (9)2007 Author(s): Lauri Vuorenkoski, STAKES Health
More informationImplementing work accident and illness insurance
Implementing work accident and illness insurance Country: Estonia Partner Institute: PRAXIS Center for Policy Studies, Tallinn Survey no: (10)2007 Author(s): Agris Koppel, Ain Aaviksoo Health Policy Issues:
More informationPerformance Payment for Family Physicians
Performance Payment for Family Physicians Country: Estonia Partner Institute: PRAXIS Center for Policy Studies, Tallinn Survey no: (6)2005 Author(s): Ain Aaviksoo Health Policy Issues: Remuneration / Payment
More informationMandatory deductible in basic health insurance
Mandatory deductible in basic health insurance Country: Netherlands Partner Institute: University of Maastricht, Department of Health Organization, Policy and Economics (BEOZ) Survey no: (11)2008 Author(s):
More information2. The stable patient case - in case when the circumstances of their health condition are neither sudden nor urgent (causing emergency).
Criteria to choose patients from waiting lists Country: Poland Partner Institute: Institute of Public Health, Jagiellonian University Medical College, Krakow Survey no: (6)2005 Author(s): Iwona Kowalska
More informationPublic insurance for dental care for chidren
Public insurance for dental care for chidren Country: Israel Partner Institute: The Myers-JDC-Brookdale Institute, Jerusalem Survey no: (16)2010 Author(s): Nir Kaidar, Tuvia Horev and Bruce Rosen Health
More informationElectronic medical records
Electronic medical records Country: France Partner Institute: Institut de Recherche et Documentation en Economie de la Santé (IRDES), Paris Survey no: (8)2006 Author(s): Chantal Cases, Philippe Le Fur
More informationRisk equalizing schemes - the next chapter
Risk equalizing schemes - the next chapter Country: Slovenia Partner Institute: Institute of Public Health of the Republic of Slovenia, Ljubljana Survey no: (7)2006 Author(s): Tit Albreht Health Policy
More informationMunicipal co-payment for health care services
Municipal co-payment for health care services Country: Denmark Partner Institute: University of Southern Denmark, Odense Survey no: (10)2007 Author(s): Ankjær-Jensen, Anni and Terkel Christiansen Health
More informationPrivate Health Insurance: more products
Private Health Insurance: more products Country: Australia Partner Institute: Centre for Health, Economics Research and Evaluation (CHERE), University of Technology, Sydney Survey no: (8)2006 Author(s):
More informationBenchmarking hospital productivity
Benchmarking hospital productivity Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (7)2006 Author(s): Miika Linna Health Policy Issues: System Organisation/
More informationMore changes to private health insurance Australia
More changes to private health insurance Australia Country: Australia Partner Institute: Centre for Health, Economics Research and Evaluation (CHERE), University of Technology, Sydney Survey no: (12) 2008
More informationFramework for rapid assessment of the pharmaceutical sector in a given country
Framework for rapid assessment of the pharmaceutical sector in a given country Prepared for Flagship Course (Health) Glossary: EU GLP GMP HIF IMS INN MOH NGO OEBIG OECD OTC PER R&D Rx TRIPS VAT WHO European
More informationMajor reductions in taxes on alcohol beverages
Major reductions in taxes on alcohol beverages Country: Finland Partner Institute: National Institute for Health and Welfare (THL), Helsinki Survey no: (5)2005 Author(s): Christoffer Tigerstedt, DPolSci,
More informationPharmaceutical Sector and
Introduction to the Pharmaceutical Sector and Rebate Contracts in Germany Dr. Frank Verheyen, Director WINEG Tim Steimle, Head of Pharmacy Department Hamburg, May 2010 General Facts about the pharmaceutical
More informationAccountable Care Organizations and Health Reform
Accountable Care Organizations and Health Reform Country: USA Partner Institute: Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management Survey no: (16)2010 Author(s):
More informationPHARMACEUTICAL MANAGEMENT PROCEDURES
PHARMACEUTICAL MANAGEMENT PROCEDURES THE FORMULARY The purpose of Coventry Health Care s formulary is to encourage use of the most cost-effective drugs. The formulary is necessary because the cost of prescription
More informationHow To Sell Medibank Private
Sale of Medibank Private Country: Australia Partner Institute: Centre for Health, Economics Research and Evaluation (CHERE), University of Technology, Sydney Survey no: (8)2006 Author(s): Marion Haas Health
More informationSmoking cessation in Leumit Health Fund
Smoking cessation in Leumit Health Fund Country: Israel Partner Institute: The Myers-JDC-Brookdale Institute, Jerusalem Survey no: (13) 2009 Author(s): Kitai E., Vardy D., Margalit A., Brami J., Matz E.,
More informationUniversal Dental Health Scheme
Universal Dental Health Scheme Country: Australia Partner Institute: Centre for Health, Economics Research and Evaluation (CHERE), University of Technology, Sydney Survey no: (13) 2009 Author(s): Gallego,
More informationUpdate on the Integrated Hospital-Community EMR
Update on the Integrated Hospital-Community EMR Country: Israel Partner Institute: The Myers-JDC-Brookdale Institute, Jerusalem Survey no: (12) 2008 Author(s): Nirel, Nurit and Revital Gross Health Policy
More informationIndependent treatment centers in the Netherlands
Independent treatment centers in the Netherlands Country: Netherlands Partner Institute: University of Maastricht, Department of Health Organization, Policy and Economics (BEOZ) Survey no: (11)2008 Author(s):
More informationThe State Of Electronic Health Records: A Strategic Plan For Ails You
Implementing Electronic Health Records: An Update Country: USA Partner Institute: Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management Survey no: (10)2007 Author(s):
More informationHow To Amend The Health Insurance Bill Of Insurance In Australia
Parliament of Australia Department of Parliamentary Services Parliamentary Library Information analysis and advice for the Parliament BILLS DIGEST 18 September 2007, no. 49, 2007 08, ISSN 1328-8091 Health
More informationThe medicines market in Norway - prices and regulations
Design and print by Grafia Kommunikasjon AS / 08-49787 / www.grafia.net. Photo by Jens Sølvberg The medicines market in Norway - prices and regulations Apotekforeningen (The Norwegian Pharmacy Association)
More informationhow to choose the health plan that s right for you
how to choose the health plan that s right for you It s easy to feel a little confused about where to start when choosing a health plan. Some people ask their friends, family, or co-workers for advice.
More informationHealth & the economic crisis: the Australian case
Health & the economic crisis: the Australian case Country: Australia Partner Institute: Centre for Health, Economics Research and Evaluation (CHERE), University of Technology, Sydney Survey no: (14) 2009
More informationNational Health Insurance Policy 2013
National Health Insurance Policy 2013 1. Background The Interim Constitution of Nepal 2007 provides for free basic health care as a fundamental right of citizens. Accordingly, the Government of Nepal has
More informationRestricting supplemental insurance services
Restricting supplemental insurance services Country: Israel Partner Institute: The Myers-JDC-Brookdale Institute, Jerusalem Survey no: (10)2007 Author(s): Gross, Revital and Shuli Brammli-Greenberg Health
More informationNew health insurance system
New health insurance system Country: Netherlands Partner Institute: Institute of Health Policy & Management, Erasmus University Rotterdam Survey no: (4)2004 Author(s): Jos Holland and André den Exter,
More informationThe Socio-economic Environment of Greece
HTA DEVELOPMENTS IN THE CENTRAL AND EASTERN EUROPEAN REGION: LOCK, STOCK & BARREL IN CHALLENGING TIMES The experience of GREECE Mary Geitona, MSc, Ph.D President ISPOR Greece Chapter As. Professor, University
More informationQuality in and Equality of Access to Healthcare Services
Quality in and Equality of Access to Healthcare Services Country Report for Finland March 2008 Kristian Wahlbeck, Kristiina Manderbacka, Lauri Vuorenkoski, Hannamaria Kuusio, Minna-Liisa Luoma, Eeva Widström
More informationGeneric Medication Prices
Generic Medication Prices By David Belk MD We ve often heard that the cost of generic prescription medications have been rising dramatically in the US; far more than the average rate of inflation. But
More informationIntroduction of a Standard Drug Formulary in Hospital Authority
Introduction of a Standard Drug Formulary in Hospital Authority PURPOSE This paper seeks Members views on the introduction of a Standard Hospital Authority Drug Formulary ( ) ( Standard Drug Formulary
More informationIntroducing... Active Pharmacy service SM. Innovative new ways to enhance benefits and reduce costs
Introducing... Active Pharmacy service SM Innovative new ways to enhance benefits and reduce costs Did you know... that healthcare costs in Canada have doubled in the last decade?* Added value and cost
More informationIMPACT FINANCIAL CONSUMER HEALTHCARE ENGAGEMENT. The. (Or, How Easy it Really is to Save Someone a Buck in This Day and Age)
The FINANCIAL IMPACT on CONSUMER ENGAGEMENT in HEALTHCARE (Or, How Easy it Really is to Save Someone a Buck in This Day and Age) How did the State of Kansas find a savings opportunity in excess of 18 million
More informationMedicine price regulation the South African experience
Medicine price regulation the South African experience Dr Anban Pillay Chief Director: Health Financing and Economics National Department of Health PillaA@health.gov.za pillayanban@yahoo.com.au Tel: +27
More informationYour pharmacy, as near as your mailbox Aetna Rx Home Delivery
Quality health plans & benefits Healthier living Financial well-being Intelligent solutions Your pharmacy, as near as your mailbox Aetna Rx Home Delivery www.aetna.com 05.02.308.1-KC B (12/13) Start saving
More informationPharmaceutical Policy in Korea: Role of Health Insurance in Pricing, Reimbursement and Monitoring
Pharmaceutical Policy in : Role of Health Insurance in Pricing, Reimbursement and Monitoring Soonman KWON* and Sukyeong KIM** *Dean, School of Public Health Seoul National University ** Director, Research
More informationPrescription drug costs continue to rise at
Prescription Drugs Developing an Effective Generic Prescription Drug Program by John D. Jones Pharmacy benefit managers (PBMs) use a variety of pricing strategies. When employers have a thorough knowledge
More informationRecycling Unused Cancer Drugs
Recycling Unused Cancer Drugs Country: USA Partner Institute: Department of Behavioral Science and Health Education, Rollins School of Public Health, Emory University Survey no: (13) 2009 Author(s): Elena
More informationThe Swedish Pharmaceutical Reimbursement System
The Swedish Pharmaceutical Reimbursement System January 2007 www.lfn.se The Swedish Pharmaceutical Reimbursement System - A brief overview Sweden made some major changes to its reimbursement system in
More informationAn introduction to the Pharmaceutical Benefits Scheme
An introduction to the Pharmaceutical Benefits Scheme Introduction The use of medicines is the most common health intervention to combat illness and disease and promote good health and wellness. Of the
More informationTHE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA
THE ORGANISATION AND FINANCING OF HEALTH CARE SYSTEM IN LATVIA Eriks Mikitis Ministry of Health of the Republic of Latvia Department of Health Care Director General facts, financial resources Ministry
More informationAccess to dental care in Australia
Access to dental care in Australia Country: Australia Partner Institute: Centre for Health, Economics Research and Evaluation (CHERE), University of Technology, Sydney Survey no: (5)2005 Author(s): Marion
More informationWHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain
WHITE PAPER The Impact of Rising Generic Drug Prices on the U.S. Drug Supply Chain Over the past two years, the pharmacy industry has seen unprecedented increases in the prices of generic drugs, causing
More informationTHE PATIENT PROTECTION AND AFFORDABLE CARE ACT (PPACA/ACA/ OBAMACARE ) & ITS IMPACT ON MUHLENBERG. 2015: What s changing and what s not!
THE PATIENT PROTECTION AND AFFORDABLE CARE ACT (PPACA/ACA/ OBAMACARE ) & ITS IMPACT ON MUHLENBERG 2015: What s changing and what s not! Affordable Care Act (ACA)- Continued Impact in 2015 In 2011, ACA
More informationPrinceton University Prescription Drug Plan Summary Plan Description
Princeton University Prescription Drug Plan Summary Plan Description Princeton University Prescription Drug Plan Summary Plan Description January 2015 Contents Introduction... 1 How the Plan Works... 2
More informationREGULATION. on the advertising of medicinal products. SECTION I Definitions, scope and general provisions.
REGULATION on the advertising of medicinal products. SECTION I Definitions, scope and general provisions. Article 1 Definitions. For the purposes of this Regulation, the following terms are used as defined
More informationPre-existing condition coverage post-health reform
Pre-existing condition coverage post-health reform Country: USA Partner Institute: Johns Hopkins Bloomberg School of Public Health, Department of Health Policy and Management Survey no: (16)2010 Author(s):
More informationI ve been asked to talk about the Pharmaceutical Benefits Scheme in the context of Medicare and the broader health sector.
1 Sustaining the PBS for the future Dr Brendan Shaw, Chief Executive, Medicines Australia Speech to 2 nd Future of Medicare Conference 11 November 2010, Sydney Thank you for the opportunity to speak with
More informationTackling runaway drug plan costs
Tackling runaway drug plan costs Drug management solutions not as tough a pill for employees to swallow Another Bright Paper brought to you by Sun Life Financial Group Benefits. September 2011 Foreword
More informationHealth financing reform idea: health fund
Health financing reform idea: health fund Country: Germany Partner Institute: Bertelsmann Stiftung, Gütersloh Survey no: (7)2006 Author(s): Melanie Zimmermann, reviewers: Reinhard Busse, Sophia Schlette
More informationGroup insurance. Generic drugs. Their positive effect on your wallet
Group insurance Generic drugs Their positive effect on your wallet A wise choice Prescription drugs have a couple of things in common: they re designed to heal us or make us feel better, and most of them
More information2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan
2015 Travelers Prescription Drug Plan Blue Cross Blue Shield Plan and United Healthcare Choice Plus Plan Plan Details, Programs, and Policies Table of Contents Click on the links below to be taken to that
More informationHospital-community electronic medical record
Hospital-community electronic medical record Country: Israel Partner Institute: The Myers-JDC-Brookdale Institute, Jerusalem Survey no: (6)2005 Author(s): Nirel Nurit, Rosen Bruce, Gross Revital Myers-JDC-Brookdale
More informationACTIVELY MANAGED DRUG SOLUTIONS. for maintenance and specialty medication. Actively Managed Drug Solutions is not available in the province of Quebec
ACTIVELY MANAGED DRUG SOLUTIONS for maintenance and specialty medication Actively Managed Drug Solutions is not available in the province of Quebec ARE YOU UNDERESTIMATING THE IMPACT OF CHRONIC DISEASE?
More informationA reliable and convenient way to optimize your prescription drug benefit
Introducing... Pharmacy Benefit Management and the Express Scripts Canada Pharmacy SM A reliable and convenient way to optimize your prescription drug benefit Did you know... that healthcare costs in Canada
More informationBarton Deakin: Commission of Audit Report Health. 7 May 2014
Barton Deakin: Commission of Audit Report Health 7 May 2014 The Report delivered to the Government by the National Commission of Audit contained several recommendations to reform the Australian health
More informationQUM and Continuity of Care A Prescribed Medicines Services and Programs
Community Pharmacy Roadmap Program Development Template Program/Service: Quadrant: 1. Program/Service Description QUM and Continuity of Care A Prescribed Medicines Services and Programs a) Background The
More informationHow does the NHS buy HIV Drugs?
The April 2011 announcement of changes to HIV drugs purchasing arrangements in London highlighted the direct impact of National Health Service (NHS) drugs procurement budgets and processes on individual
More informationNew guidelines on aesthetic treatment
New guidelines on aesthetic treatment Country: Singapore Partner Institute: Department of Epidemiology and Public Health, National University of Singapore Survey no: (12) 2008 Author(s): Lim Meng Kin Health
More informationINTERNATIONAL PRICE COMPARISON: THE CYPRIOT EXAMPLE. Athos Tsinontides Health Insurance Organisation
INTERNATIONAL PRICE COMPARISON: THE CYPRIOT EXAMPLE Athos Tsinontides Health Insurance Organisation CYPRUS CYPRUS Kypros Demographics Population (2004): Gross Domestic Product (GDP): Total Health Expenditure
More informationElectronic prescribing and dispensing of drugs
Electronic prescribing and dispensing of drugs will bring significant benefits to patients, medical professionals and to the health system as a whole. These benefits will not only have a bearing on quality
More informationPHARMACY BENEFIT DESIGN CONSIDERATIONS
PHARMACY BENEFIT DESIGN CONSIDERATIONS Is your pharmacy benefit designed for your employees or the big drug companies? The pharmacy (or prescription) benefit is one of the most sought after benefits by
More informationGlobal Forum on Competition
Unclassified DAF/COMP/GF/WD(2014)32 DAF/COMP/GF/WD(2014)32 Unclassified Organisation de Coopération et de Développement Économiques Organisation for Economic Co-operation and Development 30-Jan-2014 English
More informationfinding the balance between public and private health the example of australia
finding the balance between public and private health the example of australia By Zoe McKenzie, Senior Researcher This note provides an overview of the principal elements of Australia s public health system,
More informationA Model for Mental Health Integration
A Model for Mental Health Integration Country: USA Partner Institute: Department of Behavioral Science and Health Education, Rollins School of Public Health, Emory University Survey no: (14) 2009 Author(s):
More informationResponse to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers
Response to the New Brunswick Government Consultation on a Prescription Drug Plan for Uninsured New Brunswickers Brief submitted by The New Brunswick Nurses Union April 2012 Background The New Brunswick
More informationMaryland Medicaid Program
Maryland Medicaid Program Maryland s Pharmacy Discount Waiver Tuesday, November 19, 2002 Debbie I. Chang Deputy Secretary for Health Care Financing Maryland Department of Health and Mental Hygiene Overview
More informationUNDERSTANDING YOUR HEALTH NET PHARMACY BENEFITS Los Angeles Unified School District Learning about your pharmacy benefits can save you time and money
UNDERSTANDING YOUR HEALTH NET PHARMACY BENEFITS Los Angeles Unified School District Learning about your pharmacy benefits can save you time and money HEALTH NET MAKES USING YOUR NEW PHARMACY PLAN TROUBLE-FREE
More informationS P E C I A L I S T A N D M A S T E R S T U D I E S
University Ss, Cyril and Methodius Skopje FACULTY OF PHARMACY S P E C I A L I S T A N D M A S T E R S T U D I E S Healthcare management and pharmacoeconomics Skopje, 2007 STUDY PLAN -Specialist Studies-
More informationContinuing education for community pharmacists in Denmark the case of Master of Drug Management
Continuing education for community pharmacists in Denmark the case of Master of Drug Management Birthe Søndergaard Associate Professor Department of Pharmacology and Pharmacotherapy, Section of Social
More informationEmpire s Prescription Drug Plan
Empire s Prescription Drug Plan Empire s prescription drug program is about more than processing claims and making prescriptions available. It s about looking at each person as an individual. Because we
More informationThe Evolution of Taiwan National Health Insurance Drug Policy - Review and Analysis
The Evolution of Taiwan National Health Insurance Drug Policy - Review and Analysis Chih-Sheng (Jason) Hsu ICIUM Antalya, Turkey / Nov. 14-18, 2011 Introduction Types of Social Insurance Intervention Category
More information14 Treatment provisions
14 Treatment provisions Chapter summary The Military Rehabilitation and Compensation Act 2004 (MRCA) allows the Military Rehabilitation and Compensation Commission (MRCC) to provide treatment to a serving
More informationSENATE COMMITTEE ON LABOR AND INDUSTRIAL RELATIONS Senator Tony Mendoza, Chair 2015-2016 Regular KEY ISSUE ANALYSIS
SENATE COMMITTEE ON LABOR AND INDUSTRIAL RELATIONS Senator Tony Mendoza, Chair 2015-2016 Regular Bill No: AB 1124 Hearing Date: July 13, 2015 Author: Perea Version: June 1, 2015 Urgency: No Fiscal: Yes
More informationc. determine the factors that will facilitate/limit physician utilization of pharmacists for medication management services.
Consumer, Physician, and Payer Perspectives on Primary Care Medication Management Services with a Shared Resource Pharmacists Network Marie Smith, PharmD and Michlle Breland, PhD University of Connecticut,
More informationAccess to affordable essential medicines 1
35 Access to affordable essential medicines 1 Target 8e In cooperation with pharmaceutical companies, provide access to affordable essential drugs in developing countries. Target 8e of the Millennium Development
More informationGetting the Medications and Treatments You Need
Neuropathy Action Foundation Awareness Education Empowerment Getting the Medications and Treatments You Need Understanding Your Rights in Arizona As you search for a health insurance plan or coverage for
More informationContents. Welcome... 2. Analyzing Competition in the Pharmaceutical Industry... 6
ECONOMICS COMMITTEE NEWSLETTER Contents Welcome... 2 Call for Articles... 3 Calendar of Events... 4 Analyzing Competition in the Pharmaceutical Industry... 6 by Rahul Guha, Andrew M. Lacy and Sally Woodhouse
More informationCompPharma. Manage. Process. Inform. Ensure. The Role of a PBM in Workers Compensation
Manage Inform Process Ensure The Role of a PBM in Workers Compensation Understanding the role of workers compensation pharmacy benefit managers (WC-PBMs) can help state and local government agencies ensure
More informationBritish Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes
British Columbia Pharmacy Association (BCPhA) Clinical Service Proposal Self-Monitoring of Blood Glucose in Type 2 Diabetes Introduction Self-monitoring of blood glucose (SMBG) is in widespread use among
More informationYOUR PRESCRIPTION DRUG PLAN BENEFIT OVERVIEW. Brought to you by Medco for The Motion Picture Industry Health Plan
YOUR PRESCRIPTION DRUG PLAN BENEFIT OVERVIEW Brought to you by Medco for The Motion Picture Industry Health Plan Your prescription drug benefit* You will make your co-payments according to the schedule
More informationAchieving Excellence in Canada s Health Care System: Opportunities for Federal Leadership and Collaborative Action
Achieving Excellence in Canada s Health Care System: Opportunities for Federal Leadership and Collaborative Action Brief Submitted to the House of Commons Standing Committee on Finance August 2013 EXECUTIVE
More informationCelebrating Pork. The Dubious Success of the Medicare Drug Benefit. Dean Baker. March 2007
Celebrating Pork The Dubious Success of the Medicare Drug Benefit Dean Baker March 2007 Center for Economic and Policy Research 1611 Connecticut Avenue, NW, Suite 400 Washington, D.C. 20009 202 293 5380
More informationEmployer and Coalition Trends in Health Care Management. Participant Summary. June 2010
Employer and Coalition Trends in Health Care Management Participant Summary June 2010 Contents Participants Key Research Findings: Top Three Trends Employer Research Highlights Employer Health Coalition
More informationLEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature First Regular Session - 2015 IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO.
LEGISLATURE OF THE STATE OF IDAHO Sixty-third Legislature First Regular Session - IN THE HOUSE OF REPRESENTATIVES HOUSE BILL NO. BY HEALTH AND WELFARE COMMITTEE 0 AN ACT RELATING TO PHARMACIES; AMENDING
More informationColorado Prescription Drug Monitoring Program. Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy
Colorado Prescription Drug Monitoring Program Department of Regulatory Agencies Division of Professions and Occupations State Board of Pharmacy DORA is dedicated to preserving the integrity of the marketplace
More informationPrescription Drug Program Summary
Prescription Drug Program Summary Express Scripts is one of the most experienced full-service pharmacy benefit management firms (PBM) in the nation. Express Scripts contracts with pharmaceutical manufacturing
More informationPharmacy Outreach Program The University of Rhode Island College of Pharmacy
Pharmacy Outreach Program The University of Rhode Island College of Pharmacy Updated October 2014 Medicare provides health insurance for Aged 65 years or older Aged 65 years or less with certain disabilities
More informationAND STILL GET HIGH QUALITY CARE?
HOW CAN WE REDUCE OUR HEALTH CARE SPENDING AND STILL GET HIGH QUALITY CARE? A Choicework discussion guide from Public Agenda, developed through a collaborative research project with the Kettering Foundation
More informationOverview of the BCBSRI Prescription Management Program
Definitions Overview of the BCBSRI Prescription Management Program DISPENSING GUIDELINES mean: the prescription order or refill must be limited to the quantities authorized by your doctor not to exceed
More informationThe Honorable Alphonso Maldon, Jr. Chairman Military Compensation and Retirement Modernization Commission P. O. Box 13170 Arlington, Virginia 22209
The Honorable Alphonso Maldon, Jr. Chairman Military Compensation and Retirement Modernization Commission P. O. Box 13170 Arlington, Virginia 22209 Dear Chairman Maldon: The National Association of Chain
More informationAnthem s Prescription Drug Plan
This information applies only to clients migrating from legacy WellPoint NextRx to Express Scripts, and does not apply to new clients implementing the Anthem prescription drug plan in 2010. Anthem s Prescription
More informationAssistance with the Cost of Medications
Assistance with the Cost of Medications Pharmaceutical Companies Helping Patients Get Their Medicines By Richard J. Sagall, M.D. It's a choice no one should have to make - pay rent and buy food or get
More informationHow do I work with my pharmacy management system vendor to enable my pharmacy for e-prescribing via the Surescripts network?
Table of Contents How do I work with my pharmacy management system vendor to enable my pharmacy for e-prescribing via the Surescripts network?...1 Why should I report issues directly through my pharmacy
More information